OBM Genetics

(ISSN 2577-5790)

OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Publication Speed (median values for papers published in 2022): Submission to First Decision: 4 weeks; Submission to Acceptance: 12 weeks; Acceptance to Publication: 13 days (1-2 days of FREE language polishing included)

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Mutant Melanoma

Submission Deadline: February 28, 2021 (Open) Submit Now

Guest Editor

Michela Roberto, MD

Assistant Professor, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University "La Sapienza", Rome, Italy;
Department of Medical-Surgical Sciences and Translation Medicine, Sant'Andrea Hospital, University "La Sapienza", Rome, Italy.

Website | E-Mail

Research Interests: oncology; clinical trials; cancer biomarkers; molecular oncology; gene expression; metastasis; colorectal cancer; chemotherapy.

About This Topic

Melanoma onset and progression are associated with a high variety of activating mutations (e.g BRAF, NRAS genes, most frequently, but also c-KIT and PTEN and others). Targeted therapies showed promising results over the past years, but it is known that most responses are temporary, and almost all of patients develop a tumor relapse within one year. Different drug-resistance mechanisms underlie the progression of disease and activation of both MAPK and PI3K/AKT/mTOR pathways. Therefore, we appreciate studies about possible gene pathways involved in mutant melanoma, clinical effects of several target inhibitors, describing properly the most prominent mechanisms of both intrinsic and acquired resistance, suggestive strategies for overcoming drug resistance and the most recent alternative combination therapies, as well as about new discovered drugs.